Moore Edwina C, Berber Eren, Jin Judy, Krishnamurthy Vikram, Shin Joyce, Siperstein Allan
Endocr Pract. 2018 Oct 5. doi: 10.4158/EP-2018-0350.
With increasing recognition of more subtle presentations of primary hyperparathyroidism (pHPT), laboratory values are frequently seen in a range that would be expected for patients who have familial hypercalcemic hypocalciuria (FHH). Calcium creatinine clearance ratio (CCCR) has been advocated as a diagnostic tool to differentiate between these two disorders. However, it is limited by an indeterminate range (0.01-0.02). The aim of this study is to assess the relevance of CCCR in a modern series of patients with surgically managed pHPT.
We performed a retrospective cohort study of 1000 patients who underwent parathyroid surgery for pHPT over eleven years. CCCR was evaluated by degree of biochemical derangement, single versus multiple gland disease and interfering medications.
Patient demographics and resected histopathology were typical for a current series of patients with pHPT. In retrospect, none of the patients were suspected to have FHH post operatively. CCCR was less than 0.01 for 19.0%, between 0.01-0.02 for 43.7% and greater than 0.02 in 37.3%. Distribution of CCCR for patients free from interfering medications and different histological subtypes were the same. One third of the cohort had mild calcium elevations, more typical for FHH. Of these, almost two thirds had a CCCR in a range suspect for FHH (<0.02).
To our knowledge this is the largest series to evaluate the validity of CCCR for patients with surgically confirmed pPHT. The utility of CCCR in screening for FHH is limited, as 63% of modern patients with confirmed pHPT have low values.
随着对原发性甲状旁腺功能亢进症(pHPT)更细微表现的认识不断增加,实验室检查值常在家族性高钙血症性低钙尿症(FHH)患者预期的范围内出现。钙肌酐清除率(CCCR)已被提倡作为区分这两种疾病的诊断工具。然而,它受限于不确定范围(0.01 - 0.02)。本研究的目的是评估CCCR在一系列接受手术治疗的pHPT现代患者中的相关性。
我们对11年间因pHPT接受甲状旁腺手术的1000例患者进行了一项回顾性队列研究。通过生化紊乱程度、单发性与多发性腺体疾病以及干扰药物来评估CCCR。
患者的人口统计学特征和切除的组织病理学对于当前这一系列pHPT患者来说是典型的。回顾性分析发现,术后没有患者被怀疑患有FHH。CCCR小于0.01的患者占19.0%,在0.01 - 0.02之间的占43.7%,大于0.02的占37.3%。未使用干扰药物的患者以及不同组织学亚型的患者CCCR分布相同。该队列中有三分之一的患者钙轻度升高,这在FHH中更为典型。其中,几乎三分之二的患者CCCR处于FHH可疑范围内(<0.02)。
据我们所知,这是评估CCCR对手术确诊的pHPT患者有效性的最大系列研究。CCCR在筛查FHH方面的效用有限,因为63%确诊的现代pHPT患者其值较低。